The FAME 1 Trial: Protecting against eye damage in adults living with type 1 diabetes
Eye damage in people living with type 1 diabetes (T1D)
People living with T1D are 25 times more likely to develop vision loss than those living without the condition. The strict control of blood glucose levels necessary for the prevention of diabetic eye disease (retinopathy) is often difficult to achieve. Further, even if blood glucose levels are tightly controlled, retinopathy may still develop.
What is the FAME 1 trial?
The FAME 1 (retinopathy and fenofibrate in Adults with Type 1 diabetes) Eye Trial is a multicentre clinical trial, led by Professors. Alicia Jenkins and Anthony Keech. It is designed to test the effectiveness of a drug called fenofibrate on the development of retinopathy in adults living with T1D.
Fenofibrate has been shown to protect against the progression of eye disease in previous studies on people living with type 2 diabetes, as well as protecting against both diabetic kidney disease and nerve damage.
FAME-1 Eye is the first trial which will now test the effectiveness of fenofibrate in people living with T1D. The trial aims to determine whether at least three years of fenofibrate can protect against eye damage in adults living with T1D with existent early retinopathy. The results, if positive, can be immediately used to improve lives by changing current clinical practice.
How is the study being conducted?
According to the study design, participants receive either a placebo or fenofibrate (used to lower bloods fats) once daily. Participants will be followed up every three to six months after the conclusion of the trial, for a period of at least three years.
What impact does study hope to have for T1D?
If this study shows positive results, fenofibrate can be immediately used to improve lives for Australians living with T1D by changing current clinical practice and helping to protect against a complication that many in the community currently face or may in future.
How can I get involved or learn more about the study?
The trial has been recruiting participants since the end of 2016 and is taking place in 22 centres across Australia and New Zealand, with another two internationally (Hong Kong & Northern Ireland). Participants are currently being recruited at 20 sites in New South Wales, Queensland, South Australia, Western Australia, and Victoria.
For more information on the trial, please refer here.
For full eligibility criteria for the FAME1 Eye Study please click here.
How your gift can help make history: Research that’s changing the future of type 1 diabetes
Type 1 diabetes (T1D) is a condition which currently affects over 130,000 Australians, with a further 8 people diagnosed each day. JDRF has a vision of turning these numbers to zero and creating a world where T1D does not exist. How? By supporting the most promising research focused on finding cures and improving lives until […]
JDRF advocate Shanna McGrath receives Mark Butler Local Legend Award
Each year during National Volunteers Week, the Minister for Health, Hon Mark Butler, announces the winners of the Mark Butler MP Volunteer Awards. These awards recognise the local volunteers in his electorate, Hindmarsh, who are dedicated to improving the needs of the community organisations they represent. JDRF advocate, Shanna McGrath, was diagnosed with T1D when […]
Our 2023 Volunteer of the Year winners
It’s National Volunteer Week and this year’s theme is ‘change makers’. At JDRF, we know that no change for type 1 diabetes (T1D) has happened without the dedication of volunteers across the community. We are an organisation who was founded by volunteers and is still powered by them, including (but not limited to!) our amazing […]
Dr Ki Wook Kim awarded JDRF Career Development Award to improve type 1 diabetes risk prediction
Dr Ki Wook Kim, a prominent Australian researcher and emerging leader in type 1 diabetes (T1D) research based at the UNSW Sydney, has been awarded a JDRF Career Development Award (CDA) with US $1M funding committed over the next five years. Dr Kim is one of only 13 Australians to ever receive the JDRF Career […]